Scarica l'app Stockscreener
4.57
0.44%
0.02
Precedente Chiudi:
$4.55
Aprire:
$4.55
Volume 24 ore:
99,208
Relative Volume:
0.70
Capitalizzazione di mercato:
$40.31M
Reddito:
$1.07M
Utile/perdita netta:
$-18.24M
Rapporto P/E:
-2.1501
EPS:
-2.1255
Flusso di cassa netto:
$-17.26M
1 W Prestazione:
+0.66%
1M Prestazione:
+114.55%
6M Prestazione:
+71.52%
1 anno Prestazione:
+74.43%
Intervallo 1D:
$4.55
$4.62
Intervallo di 1 settimana:
$4.51
$4.62
Portata 52W:
$1.81
$4.8918
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Nome
Lisata Therapeutics Inc
Settore
Industria
Telefono
908-229-2590
Indirizzo
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
4.57 | 40.13M | 1.07M | -18.24M | -17.26M | -2.1255 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lisata Therapeutics Inc Borsa (LSTA) Ultime notizie
Will Lisata Therapeutics Inc. (8NE) stock benefit from sector leadershipMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Swing Trade: Can SILA withstand a market correctionTrade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Signal Recap: Will Lisata Therapeutics Inc stock benefit from M ARisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
What Does the Market Think About Lisata Therapeutics Inc? - Benzinga
Halper Sadeh LLC Investigates Potential Violations by Multiple Companies - intellectia.ai
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Lisata regains full rights to certepetide in Greater China region By Investing.com - Investing.com Canada
Deal Watch: Kuva Labs To Go Public Via Merger With Licensing Partner Lisata - Citeline News & Insights
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA - Sahm
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement By Investing.com - Investing.com South Africa
Lisata Therapeutics and Qilu Pharmaceutical end certepetide license agreement - Investing.com Nigeria
Lisata regains full rights to certepetide in Greater China region - Investing.com
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - marketscreener.com
Lisata Therapeutics (LSTA) Ends Licensing Agreement with Qilu Ph - GuruFocus
Lisata Therapeutics ends Qilu certepetide collaboration deal - TipRanks
Lisata regains China rights to pancreatic cancer drug - Proactive financial news
Lisata Therapeutics and Qilu Pharmaceutical Terminate License Agreement - TradingView
Cancer drug rights shift: Lisata takes back certepetide in China - stocktitan.net
Lisata shares nearly double on buyout offer: Here are the details - MSN
Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals - RTTNews
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Kuva Labs to acquire Lisata Therapeutics for $4 per share By Investing.com - Investing.com Nigeria
Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva - The Globe and Mail
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook - Yahoo Finance
Lisata Therapeutics (LSTA) Downgraded by Brookline Capital | LST - GuruFocus
Halper Sadeh Investigates Fairness of Lisata's $4.00 Sale to Kuva Labs - Intellectia AI
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - The AI Journal
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Asianet Newsable
Lisata Therapeutics to be Acquired by Kuva Labs for $4.00 Per Share - citybiz
Kuva Labs, Inc. entered into a binding term sheet to acquire Lisata Therapeutics, Inc. for $36.7 million. - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results - Benzinga
Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson... - Proactive financial news
Lisata stock soars after Kuva Labs acquisition offer at 85% premium By Investing.com - Investing.com South Africa
Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Nigeria
Lisata Therapeutics Signs Binding Term Sheet With Kuva Labs - TradingView
Lisata To Be Acquired By Kuva Labs For $4/shr; Stock Soars Over 80% - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal - Proactive financial news
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs for $4 per Share - intellectia.ai
Lisata Therapeutics (LSTA) Agrees to Acquisition by Kuva Labs - GuruFocus
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal - Nasdaq
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share in an all-cash tender offer - marketscreener.com
Lisata Therapeutics Enters Binding Agreement for Acquisition by Kuva Labs with Significant Premium for Stockholders - Quiver Quantitative
Kuva Labs to acquire Lisata Therapeutics for $4 per share - Investing.com
Lisata Therapeutics To Be Acquired By Kuva Labs For $4.00 Per Share In An All-Cash Tender Offer - TradingView
Lisata Therapeutics Inc Azioni (LSTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):